USD 84.38
| ticker | 1 day return % | 1 week return % | 1 month return % | 3 months return % | 6 months return % | 1 year return % | 3 years return % | 5 years return % | 10 years return % | maximum return % |
|---|---|---|---|---|---|---|---|---|---|---|
| DXCM | -0.5 | 6.1 | 8.5 | 21.3 | -26.4 | -32.7 | -21.5 | 46.2 | 486.8 | 2770.1 |
| S&P 500 | 1.0 | 1.8 | -0.9 | 2.7 | 7.3 | 26.5 | 31.0 | 80.1 | 196.5 | 33856.2 |
Our interactive price chart includes various drawing tools to help you analyze the product more effectively. Below is a quick guide on how to use these tools: Full Guideline
Feel free to experiment with these tools to enhance your technical analysis. Remember, any drawings you make are temporary and will be lost upon refreshing the page unless saved as an image using the 'Camera' icon.
Get instant AI-powered professional insights on prices:
💡Generate AI Technical Analysis ReportA Multi-Interval Candlestick Chart displays the price movements of an asset over different time intervals. Each candlestick represents the open, high, low, and close prices for a specific interval. The chart can be used to identify trends and patterns in price movements.
| Attribute | Value |
|---|---|
| symbol | DXCM |
| name | DexCom, Inc. |
| price | 84.38 |
| changes percentage | -0.54 |
| change | -0.46 |
| day low | 83.89 |
| day high | 86.33 |
| year high | 142 |
| year low | 62.34 |
| market cap | 32958406100 |
| price avg 50 | 77.09 |
| price avg 200 | 93.11 |
| exchange | NASDAQ |
| volume | 5038032 |
| avg volume | 3968640 |
| open | 86.32 |
| previous close | 84.84 |
| eps | 1.65 |
| pe | 51.14 |
| earnings announcement | 2025-02-13T21:00:00.000+0000 |
| shares outstanding | 390595000 |
| timestamp | 2025-01-17 21:00:02 |
We derive the score of a company's financial statements by evaluating the weighted average sentiment across key within the statements. The cumulative score, normalized to a sum of 1, serves as a metric for assessing the company's performance during the specified period. A higher score indicates stronger performance. However, it's crucial to note that while this score provides valuable insights, it is just one of many factors to consider when making informed investment decisions. A holistic evaluation, considering various aspects of the company's financial health and market conditions, is essential for a well-rounded investment strategy.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001093557 | |||
| revenue | 3622300000 | 2909800000 | 24.49 |
| gross profit | 2288900000 | 1883100000 | 21.55 |
| gross profit ratio | 0.63 | 0.65 | -2.36 |
| research and development expenses | 505800000 | 484200000 | 4.46 |
| operating expenses | 1691200000 | 1491900000 | 13.36 |
| interest income | 135000000 | 18000000 | 650.00 |
| interest expense | 20300000 | 18600000 | 9.14 |
| ebitda | 916700000 | 565300000 | 62.16 |
| ebitdaratio | 0.25 | 0.14 | 76.63 |
| operating income | 597700000 | 391200000 | 52.79 |
| operating income ratio | 0.17 | 0.13 | 22.73 |
| net income | 541500000 | 341200000 | 58.70 |
| net income ratio | 0.15 | 0.12 | 27.49 |
| eps | 1.44 | 0.88 | 63.64 |
Revenue Growth: revenue increased to 3,622 million in 2023 from 2,910 million in 2022 representing a change of 24.49%. This indicates a sales growth, which is a positive sign for the company.
Gross Profit: Gross Profit increased to 2,289 million in 2023 from 1,883 million in 2022 representing a change of 21.55%. This indicates a sales profitability growth, which is a positive sign for the company.
Research and Development (R&D) Expenses: R&D Expenses increased to 506 million in 2023 from 484 million in 2022 representing a change of 4.46%. This shows that the company continues to invest in innovation and product development, which is crucial for long-term growth.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased to 917 million in 2023 from 565 million in 2022 representing a change of 62.16%. The increase in EBITDA indicates improved operational efficiency and profitability.
Operating Income: Operating income increased to 598 million in 2023 from 391 million in 2022 representing a change of 52.79%. The increase in operating income indicates better operational performance and increased profitability.
Net Income: Net income increased to 542 million in 2023 from 341 million in 2022 representing a change of 58.7%. The increase in net income shows improved profitability and indicates that the company is generating more profit for each dollar of revenue.
Earnings per Share (EPS): EPS increased to 1.44 in 2023 from 1.44 in 2022 representing a change of 63.64%. This indicates that the company's earnings are increasing and it is becoming more profitable on a per-share basis.
Operating Expenses: Operating Expenses increased to 1,691 million in 2023 from 1,492 million in 2022 representing a change of 13.36%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001093557 | |||
| revenue | 994200000 | 1004300000 | -1.01 |
| gross profit | 593800000 | 626700000 | -5.25 |
| gross profit ratio | 0.6 | 0.62 | -4.29 |
| research and development expenses | 135400000 | 136000000 | -0.44 |
| operating expenses | 441800000 | 468700000 | -5.74 |
| interest income | 32000000 | 36200000 | -11.60 |
| interest expense | 4700000 | 4800000 | -2.08 |
| ebitda | 237400000 | 244700000 | -2.98 |
| ebitdaratio | 0.24 | 0.21 | 14.14 |
| operating income | 152000000 | 158000000 | -3.80 |
| operating income ratio | 0.15 | 0.16 | -2.82 |
| net income | 134600000 | 143500000 | -6.20 |
| net income ratio | 0.14 | 0.14 | -5.25 |
| eps | 0.35 | 0.36 | -2.78 |
Revenue Growth: revenue increased to 994 million in 2024Q3 from 1,004 million in 2024Q2 representing a change of -1.01%. This indicates a sales growth, which is a positive sign for the company.
Operating Expenses: Operating Expenses decreased to 442 million in 2024Q3 from 469 million in 2024Q2 representing a change of -5.74%. The decrease in operating expenses can be attributed to various factors such as improved profitability, cost optimization and financial stability, lower operating expenses can be positive indicators.
Gross Profit: Gross Profit decreased to 594 million in 2024Q3 from 627 million in 2024Q2 representing a change of -5.25%. This indicates a sales profitability decline, which is a negative sign for the company.
Research and Development (R&D) Expenses: R&D Expenses decreased to 135 million in 2024Q3 from 136 million in 2024Q2 representing a change of -0.44%. This shows that the company decreased investment in innovation and product development, which is not a good sign for long-term growth.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) decreased to 237 million in 2024Q3 from 245 million in 2024Q2 representing a change of -2.98%. The decrease in EBITDA indicates declined operational efficiency and profitability.
Operating Income: Operating income decreased to 152 million in 2024Q3 from 158 million in 2024Q2 representing a change of -3.8%. The decrease in operating income indicates worse operational performance and decreased profitability.
Net Income: Net income decreased to 135 million in 2024Q3 from 144 million in 2024Q2 representing a change of -6.2%. The decrease in net income shows worsen profitability and indicates that the company is generating less profit for each dollar of revenue.
Earnings per Share (EPS): EPS increased to 0.35 in 2024Q3 from 0.35 in 2024Q2 representing a change of -2.78%. This indicates that the company's earnings are decreasing and it is becoming less profitable on a per-share basis.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001093557 | |||
| total assets | 6264500000 | 5391700000 | 16.19 |
| total liabilities | 4195899999 | 3259900000 | 28.71 |
| total equity | 2068600000 | 2131800000 | -2.96 |
| cash and cash equivalents | 566300000 | 642300000 | -11.83 |
| short term investments | 2157800000 | 1813900000 | 18.96 |
| long term investments | 38500000 | 19000000 | 102.63 |
| total current assets | 4425900000 | 3668800000 | 20.64 |
| total non current assets | 1838600000 | 1722900000 | 6.72 |
| total current liabilities | 1556000000 | 1839300000 | -15.40 |
| total non current liabilities | 2639899999 | 1420600000 | 85.83 |
| common stock | 400000 | 400000 | 0.00 |
| retained earnings | 1021400000 | 479900000 | 112.84 |
| total debt | 2594000000 | 2085400000 | 24.39 |
Total Assets: Total Assets increased to 6,264 million in 2023 from 5,392 million in 2022 representing a change of 16.19%. Suggesting a growth in asset holdings.
Short Term Investments: Short Term Investments increased to 2,158 million in 2023 from 1,814 million in 2022 representing a change of 18.96%. This indicates an increase in short-term investment holdings.
Total Current Assets: Total Current Assets increased to 4,426 million in 2023 from 3,669 million in 2022 representing a change of 20.64%. This indicates a better liquidity position.
Total Current Liabilities: Total Current Liabilities decreased to 1,556 million in 2023 from 1,839 million in 2022 representing a change of -15.4%. This indicates a lower short-term debt burden.
Retained Earnings: Retained Earnings increased to 1,021 million in 2023 from 480 million in 2022 representing a change of 112.84%. This indicates an accumulated profits.
Total Liabilities: Total Liabilities increased to 4,196 million in 2023 from 3,260 million in 2022 representing a change of 28.71%. This indicates an increase in overall liabilities.
Total Equity: Total Equity decreased to 2,069 million in 2023 from 2,132 million in 2022 representing a change of -2.96%. This indicates a decrease in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 566 million in 2023 from 642 million in 2022 representing a change of -11.83%. This indicates a decrease in available liquid assets.
Total Debt: Total Debt increased to 2,594 million in 2023 from 2,085 million in 2022 representing a change of 24.39%. This indicates an increase in overall debt burden.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001093557 | |||
| total assets | 6353800000 | 6799200000 | -6.55 |
| total liabilities | 4374800000 | 4364900000 | 0.23 |
| total equity | 1979000000 | 2434300000 | -18.70 |
| cash and cash equivalents | 621200000 | 939200000 | -33.86 |
| short term investments | 1871100000 | 2181500000 | -14.23 |
| long term investments | 46300000 | 43600000 | 6.19 |
| total current assets | 4262800000 | 4848400000 | -12.08 |
| total non current assets | 2091000000 | 1950800000 | 7.19 |
| total current liabilities | 1734500000 | 1722200000 | 0.71 |
| total non current liabilities | 2640300000 | 2642700000 | -0.09 |
| common stock | 400000 | 400000 | 0.00 |
| retained earnings | 1445900000 | 1311300000 | 10.26 |
| total debt | 2591200000 | 2594300000 | -0.12 |
Total Assets: Total Assets decreased to 6,354 million in 2024Q3 from 6,799 million in 2024Q2 representing a change of -6.55%. Suggesting a decrease in asset holdings.
Total Liabilities: Total Liabilities increased to 4,375 million in 2024Q3 from 4,365 million in 2024Q2 representing a change of 0.23%. This indicates an increase in overall liabilities.
Total Equity: Total Equity decreased to 1,979 million in 2024Q3 from 2,434 million in 2024Q2 representing a change of -18.7%. This indicates a decrease in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 621 million in 2024Q3 from 939 million in 2024Q2 representing a change of -33.86%. This indicates a decrease in available liquid assets.
Short Term Investments: Short Term Investments decreased to 1,871 million in 2024Q3 from 2,182 million in 2024Q2 representing a change of -14.23%. This indicates a decrease in short-term investment holdings.
Total Current Assets: Total Current Assets decreased to 4,263 million in 2024Q3 from 4,848 million in 2024Q2 representing a change of -12.08%. This indicates a worsen liquidity position.
Total Current Liabilities: Total Current Liabilities increased to 1,734 million in 2024Q3 from 1,722 million in 2024Q2 representing a change of 0.71%. This indicates a higher short-term debt burden.
Retained Earnings: Retained Earnings increased to 1,446 million in 2024Q3 from 1,311 million in 2024Q2 representing a change of 10.26%. This indicates an accumulated profits.
Total Debt: Total Debt decreased to 2,591 million in 2024Q3 from 2,594 million in 2024Q2 representing a change of -0.12%. This indicates a reduction in overall debt burden.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001093557 | |||
| net change in cash | -75800000 | -410300000 | 81.53 |
| operating cash flow | 748500000 | 669500000 | 11.80 |
| free cash flow | 511900000 | 304700000 | 68.00 |
| capital expenditure | -236600000 | -364800000 | 35.14 |
| depreciation and amortization | 186000000 | 155900000 | 19.31 |
| deferred income tax | -55000000 | -21600000 | -154.63 |
| stock based compensation | 150800000 | 126500000 | 19.21 |
| accounts payables | 466500000 | 295100000 | 58.08 |
| inventory | 0 | 49300000 | -100.00 |
| acquisitions net | 0 | -3900000 | 100.00 |
| investments in property plant and equipment | -236600000 | -364800000 | 35.14 |
| net cash used for investing activites | -507200000 | -521500000 | 2.74 |
| debt repayment | 443300000 | 0 | NaN |
| common stock issued | 26600000 | 22500000 | 18.22 |
| common stock repurchased | -688700000 | -557700000 | -23.49 |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | -318600000 | -552500000 | 42.33 |
| cash at end of period | 567500000 | 643300000 | -11.78 |
| accounts receivables | 0 | -199900000 | 100.00 |
| cash at beginning of period | 643300000 | 1053600000 | -38.94 |
Net Change in Cash: Net Change in Cash increased to -76 million in 2023 from -410 million in 2022 representing a change of 81.53%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow increased to 748 million in 2023 from 670 million in 2022 representing a change of 11.8%. This indicates that the company generated more cash from its core business operations.
Free Cash Flow: Free Cash Flow increased to 512 million in 2023 from 305 million in 2022 representing a change of 68.0%. This indicates an increase in cash generated after accounting for capital expenditures.
Capital Expenditure: Capital Expenditure increased to -237 million in 2023 from -365 million in 2022 representing a change of 35.14%. This indicates an increase in the cash outflow required for acquiring or improving long-term assets.
Stock-Based Compensation: Stock-Based Compensation increased to 151 million in 2023 from 126 million in 2022 representing a change of 19.21%. This indicates increased expenses, which is generally considered a negative sign from a financial perspective.
Accounts Payables: The absolute value of Accounts Payables increased to 466 million in 2023 from 295 million in 2022 representing a change of 58.08%. This indicates that the company has increased its outstanding obligations to its suppliers.
Accounts Receivables: Accounts Receivables increased to 0 in 2023 from -200 million in 2022 representing a change of 100.0%. This suggests that the company is less capable of collecting payments from its customers.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001093557 | |||
| operating cash flow | 199500000 | 279400000 | -28.60 |
| free cash flow | 88300000 | 213300001 | -58.60 |
| capital expenditure | -111200000 | -66099999 | -68.23 |
| depreciation and amortization | 55300000 | 52100000 | 6.14 |
| deferred income tax | -11600000 | -14700000 | 21.09 |
| stock based compensation | 43400000 | 44700000 | -2.91 |
| accounts receivables | -55600000 | 33800000 | -264.50 |
| accounts payables | 49800000 | 72300000 | -31.12 |
| inventory | -1900000 | 18300000 | -110.38 |
| acquisitions net | 0 | 0 | NaN |
| investments in property plant and equipment | -111200000 | -66099999 | -68.23 |
| net cash used for investing activites | 210300000 | -188900000 | 211.33 |
| debt repayment | 0 | 0 | NaN |
| common stock issued | 14800000 | 0 | NaN |
| common stock repurchased | -750000000 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | -736500000 | -1400000 | -52,507.14 |
| net change in cash | -316800000 | 88000000 | -460.00 |
| cash at end of period | 622400000 | 939200000 | -33.73 |
| cash at beginning of period | 939200000 | 851200000 | 10.34 |
Net Change in Cash: Net Change in Cash decreased to -317 million in 2024Q3 from 88 million in 2024Q2 representing a change of -460.0%. Indicating a declined ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow decreased to 200 million in 2024Q3 from 279 million in 2024Q2 representing a change of -28.6%. This indicates that the company generated less cash from its core business operations.
Free Cash Flow: Free Cash Flow decreased to 88 million in 2024Q3 from 213 million in 2024Q2 representing a change of -58.6%. This indicates a decrease in cash generated after accounting for capital expenditures.
Deferred Income Tax: Deferred Income Tax increased to -12 million in 2024Q3 from -15 million in 2024Q2 representing a change of 21.09%. This indicates that the company's tax liability for future periods has increased.
Capital Expenditure: Capital Expenditure decreased to -111 million in 2024Q3 from -66 million in 2024Q2 representing a change of -68.23%. This indicates a possible improved efficiency or a shift in the company's strategic priorities.
Stock-Based Compensation: Stock-Based Compensation decreased to 43 million in 2024Q3 from 45 million in 2024Q2 representing a change of -2.91%. This indicates decreased expenses, which is generally considered a positive sign from a financial perspective.
Accounts Payables: The absolute value of Accounts Payables decreased to 50 million in 2024Q3 from 72 million in 2024Q2 representing a change of -31.12%. This indicates that the company has reduced its outstanding obligations to its suppliers.
Accounts Receivables: Accounts Receivables decreased to -56 million in 2024Q3 from 34 million in 2024Q2 representing a change of -264.5%. This suggests that the company has been able to collect payments from its customers more efficiently and timely.
We save you time by utilizing Generative AI to summarize earnings transcripts. Our summaries provide a clear insight into the company's current performance, future outlook, and overall sentiment expressed during the call. Click on below links to explore more.
Note: The years mentioned below are fiscal years in accounting.
Q3 2024 Earnings call transcript
EPS represents the portion of a company's profit allocated to each outstanding share of common stock. A higher EPS is generally favorable, indicating stronger profitability on a per-share basis.
Positive EPS: A positive EPS signifies that a company is profitable, it is generally viewed positively, supporting stock value and investor confidence.
Negative EPS: Indicates that a company is operating at a loss, which could lead to negative sentiment, potential stock depreciation, and concerns about the company's financial health.
The Next Earning Date represents when the company plans to release its next set of financial results.
An upward trend in EPS suggests consistent growth in earnings, often leading to increased investor confidence. A downward trend may indicate a decline in earnings, potentially decreasing investor confidence and stock value. Fluctuating EPS suggests unpredictable financial performance, warranting cautious investor analysis.
Earnings surprise occurs when a company's actual earnings differ from analysts' expectations. A positive earnings surprise typically reflects better-than-expected performance, potentially leading to stock appreciation. Conversely, a negative earnings surprise can result in stock depreciation. An earnings surprise of zero means the earnings met expectations, which typically has a neutral impact on stock price.
Discover detailed analyst recommendations for stocks, including categories such as Buy, Hold, Sell, Strong Buy, and Strong Sell. These insights are based on thorough analysis of financial and market factors. The consensus is calculated by assigning a numerical score to each recommendation. These scores are then weighted and averaged over a specified period to provide a comprehensive view of the stock's outlook, with the final score determining the overall consensus.
| 2023-12-31 | 2022-12-31 | Y/Y change % | |
|---|---|---|---|
| FY | |||
| calendar year | 2023 | 2022 | NaN |
| revenue per share | 9.38 | 7.47 | 25.58 |
| net income per share | 1.4 | 0.88 | 60.10 |
| operating cash flow per share | 1.94 | 1.72 | 12.78 |
| free cash flow per share | 1.33 | 0.78 | 69.48 |
| cash per share | 7.06 | 6.31 | 11.88 |
| book value per share | 5.36 | 5.47 | -2.11 |
| tangible book value per share | 4.95 | 4.96 | -0.37 |
| shareholders equity per share | 5.36 | 5.47 | -2.11 |
| interest debt per share | 6.77 | 5.4 | 25.35 |
| market cap | 47898740000 | 44095656000 | 8.62 |
| enterprise value | 49926440000 | 45538756000 | 9.64 |
| pe ratio | 88.46 | 129.24 | -31.56 |
| price to sales ratio | 13.22 | 15.15 | -12.74 |
| pocfratio | 63.99 | 65.86 | -2.84 |
| pfcf ratio | 93.57 | 144.72 | -35.34 |
| pb ratio | 23.16 | 20.68 | 11.94 |
| ptb ratio | 23.16 | 20.68 | 11.94 |
| ev to sales | 13.78 | 15.65 | -11.93 |
| enterprise value over ebitda | 54.46 | 80.56 | -32.39 |
| ev to operating cash flow | 66.7 | 68.02 | -1.94 |
| ev to free cash flow | 97.53 | 149.45 | -34.74 |
| earnings yield | 0.01 | 0.01 | 46.10 |
| free cash flow yield | 0.01 | 0.01 | 54.66 |
| debt to equity | 1.25 | 0.98 | 28.19 |
| debt to assets | 0.41 | 0.39 | 7.06 |
| net debt to ebitda | 2.21 | 2.55 | -13.35 |
| current ratio | 2.84 | 1.99 | 42.60 |
| interest coverage | 29.44 | 21.03 | 39.99 |
| income quality | 1.38 | 1.96 | -29.55 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0.28 | 0.3 | -6.94 |
| research and ddevelopement to revenue | 0.14 | 0.17 | -16.09 |
| intangibles to total assets | 0.03 | 0.04 | -30.93 |
| capex to operating cash flow | 0.32 | 0.54 | -41.99 |
| capex to revenue | 0.07 | 0.13 | -47.90 |
| capex to depreciation | 1.27 | 2.34 | -45.64 |
| stock based compensation to revenue | 0.04 | 0.04 | -4.24 |
| graham number | 13.01 | 10.39 | 25.19 |
| roic | 0.1 | 0.08 | 22.56 |
| return on tangible assets | 0.09 | 0.07 | 34.99 |
| graham net net | -1.17 | -0.22 | -428.25 |
| working capital | 2869900000 | 1829500000 | 56.87 |
| tangible asset value | 1908900001 | 1932800000 | -1.24 |
| net current asset value | 230000001 | 408900000 | -43.75 |
| invested capital | 4214100000 | 3164100000 | 33.18 |
| average receivables | 869850000 | 634400000 | 37.11 |
| average payables | 257150000 | 213650000 | 20.36 |
| average inventory | 433150000 | 332000000 | 30.47 |
| days sales outstanding | 99.51 | 94.35 | 5.46 |
| days payables outstanding | 75.66 | 84.58 | -10.54 |
| days of inventory on hand | 153.18 | 109.03 | 40.49 |
| receivables turnover | 3.67 | 3.87 | -5.18 |
| payables turnover | 4.82 | 4.32 | 11.78 |
| inventory turnover | 2.38 | 3.35 | -28.82 |
| roe | 0.26 | 0.16 | 63.55 |
| capex per share | 0.61 | 0.94 | -34.57 |
ROE: Return on Equity (ROE) increased to 0.26 on 2023-12-31 from 0.16 on 2022-12-31, representing a change of 63.55%. Suggesting the company has been generating high returns for its shareholders.
Current Ratio: Current Ratio increased to 2.84 on 2023-12-31 from 1.99 on 2022-12-31, representing a change of 42.60%. The current ratio has been increasing, suggesting an increase in the company's short-term liquidity. Also, it's above 1, indicating the ability to cover short-term obligations.
PE Ratio: Price-to-Earnings (P/E) Ratio decreased to 88.46 on 2023-12-31 from 129.24 on 2022-12-31, representing a change of -31.56%. Indicating a decrease in the relative valuation of the company's stock.
Debt-to-Equity Ratio:
| 2024-09-30 Q3 | 2024-06-30 Q2 | Q/Q change % | |
|---|---|---|---|
| DXCM | |||
| calendar year | 2024 | 2024 | NaN |
| revenue per share | 2.52 | 2.52 | 0.25 |
| net income per share | 0.34 | 0.36 | -5.01 |
| operating cash flow per share | 0.51 | 0.7 | -27.69 |
| free cash flow per share | 0.22 | 0.53 | -58.08 |
| cash per share | 6.32 | 7.82 | -19.12 |
| book value per share | 5.02 | 6.1 | -17.67 |
| tangible book value per share | 4.69 | 5.75 | -18.46 |
| shareholders equity per share | 5.02 | 6.1 | -17.67 |
| interest debt per share | 6.59 | 6.51 | 1.14 |
| market cap | 26427168000.0 | 44778264000 | -40.98 |
| enterprise value | 28397168000.0 | 46433364000 | -38.84 |
| pe ratio | 49.08 | 78.01 | -37.08 |
| price to sales ratio | 26.58 | 44.59 | -40.38 |
| pocfratio | 132.47 | 160.27 | -17.35 |
| pfcf ratio | 299.29 | 209.93 | 42.57 |
| pb ratio | 13.35 | 18.39 | -27.40 |
| ptb ratio | 13.35 | 18.39 | -27.40 |
| ev to sales | 28.56 | 46.23 | -38.22 |
| enterprise value over ebitda | 119.62 | 189.76 | -36.96 |
| ev to operating cash flow | 142.34 | 166.19 | -14.35 |
| ev to free cash flow | 321.6 | 217.69 | 47.73 |
| earnings yield | 0.01 | 0.0 | 58.93 |
| free cash flow yield | 0.0 | 0.0 | -29.86 |
| debt to equity | 1.31 | 1.07 | 22.86 |
| debt to assets | 0.41 | 0.38 | 6.88 |
| net debt to ebitda | 8.3 | 6.76 | 22.69 |
| current ratio | 2.46 | 2.82 | -12.70 |
| interest coverage | 32.34 | 32.92 | -1.75 |
| income quality | 1.48 | 1.95 | -23.88 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0 | 0 | NaN |
| research and ddevelopement to revenue | 0.14 | 0.14 | 0.57 |
| intangibles to total assets | 0.02 | 0.02 | 0.95 |
| capex to operating cash flow | 0.56 | 0.24 | 135.61 |
| capex to revenue | 0.11 | 0.07 | 69.94 |
| capex to depreciation | 2.01 | 1.27 | 58.50 |
| stock based compensation to revenue | 0.04 | 0.04 | -1.92 |
| graham number | 6.21 | 7.02 | -11.57 |
| roic | 0.02 | 0.02 | 4.87 |
| return on tangible assets | 0.02 | 0.02 | 0.39 |
| graham net net | -2.07 | -0.53 | -292.53 |
| working capital | 2528300000 | 3126200000 | -19.13 |
| tangible asset value | 1849000000 | 2296500000 | -19.49 |
| net current asset value | -112000000 | 483500000 | -123.16 |
| invested capital | 4044600000 | 4518300000 | -10.48 |
| average receivables | 1016200000 | 991750000 | 2.47 |
| average payables | 316800000 | 288350000 | 9.87 |
| average inventory | 578300000 | 579700000 | -0.24 |
| days sales outstanding | 93.58 | 89.5 | 4.56 |
| days payables outstanding | 73.41 | 73.17 | 0.33 |
| days of inventory on hand | 131.79 | 135.93 | -3.05 |
| receivables turnover | 0.96 | 1.01 | -4.36 |
| payables turnover | 1.23 | 1.23 | -0.33 |
| inventory turnover | 0.68 | 0.66 | 3.14 |
| roe | 0.07 | 0.06 | 15.38 |
| capex per share | 0.28 | 0.17 | 70.36 |
ROE:
Debt-to-Equity Ratio:
PE Ratio: Price-to-Earnings (P/E) Ratio decreased to 49.08 on 2024-09-30 Q3 from 78.01 on 2024-06-30 Q2, representing a change of -37.08%. Indicating a decrease in the relative valuation of the company's stock.
Current Ratio: Current Ratio decreased to 2.46 on 2024-09-30 Q3 from 2.82 on 2024-06-30 Q2, representing a change of -12.70%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. However, it is still above 1, indicating the ability to cover short-term obligations.
Negative Sentiment: Discounted Cash Flow value is 33.22 which is lower than current price 84.38, indicates the company may be overvalued.
| Market Capitalization | Enterprise Value | |
|---|---|---|
| Definition | The total market value of a company's outstanding shares | The total market value of a company, including its debt and other liabilities |
| Calculation | Current share price * Total number of outstanding shares | Market capitalization + Total debt - Cash and cash equivalents |
| Focus | Equity component of a company's value | Total economic value of a company |
| Usefulness | Assesses a company's size and growth potential based on investor sentiment | Provides a more comprehensive valuation that considers both equity and debt |
Analyzing dividends is a crucial aspect of investment evaluation, offering valuable insights into a company's financial health and its commitment to shareholder returns. Dividends represent a portion of a company's profits distributed to its shareholders, providing a steady income stream. We help you analyze dividends based on the indicators mentioned below:
• Investors often assess the average dividend amount, observing trends over time to gauge the company's stability and growth potential. A positive trend in average dividends indicates a consistent and potentially lucrative investment. Additionally, evaluating the trend of dividend increases provides insight into the company's financial strength and management's confidence in future earnings.
• Consistency in paying dividends is a reassuring sign, reflecting a company's reliability and commitment to shareholder value. For investors, dividends not only offer income but also contribute to the overall total return on investment.
• Companies with a history of regular and increasing dividends can attract income-focused investors seeking stable returns, making dividends a critical factor in building a well-rounded investment portfolio.
Interested in the overall sentiment for a particular period? Check out our news sentiment analysis tool.
Sentiment: Negative
Publish Date: 2025-01-17 16:43:21
DexCom, Inc.'s growth is impressive but limited by its niche market, with my projected ceiling being ~$7.5bn in peak annual revenues. Despite positive Q4 2024 results, DexCom's stock is fairly valued, with muted enthusiasm from Wall Street today, and a "Hold" rating for me for 2025. I suspect the market overestimated DexCom's mass-market potential, leading to a reality check and a savage bear run on its stock in the past year.
Sentiment: Positive
Publish Date: 2025-01-16 05:22:00
Stocks tend to perform well in January, but that's not a good reason to invest this month. Strong returns aren't made in a single 30-day period.
Sentiment: Positive
Publish Date: 2025-01-14 09:16:08
DXCM's top line reflects strong demand for its CGM sensors. International expansion is also driving sales higher.
Sentiment: Positive
Publish Date: 2025-01-13 09:26:13
DXCM continues to raise optimism among investors owing to its strong product portfolio.
Sentiment: Positive
Publish Date: 2025-01-13 07:43:32
Dexcom forecast total annual revenue in line with Wall Street expectations on Monday, on bets of strong demand for its continuous glucose monitors for diabetes patients.
Sentiment: Neutral
Publish Date: 2025-01-13 07:30:00
SAN DIEGO--(BUSINESS WIRE)--Dexcom Reports Preliminary, Unaudited Results for the Fourth Quarter and Fiscal Year 2024 and Initial 2025 Outlook.
Sentiment: Neutral
Publish Date: 2025-01-08 08:30:00
The past year was a great one for the stock market as a whole, but there were plenty of companies that didn't do well in 2024. Shares of Celsius Holdings (CELH 0.93%), DexCom (DXCM -0.66%), and Nike (NKE 0.12%) all fell by more than 30% during the year, as investors weren't thrilled with their results.
Sentiment: Positive
Publish Date: 2025-01-04 07:45:00
Now that we've shut the door on 2024, it's useful to look back at some of the best -- and, on the flip side, some of the worst -- performers of the year on the stock market. Many outliers were in the tech sector, so it's worth taking a look at the tech-heavy Nasdaq-100 index.
Sentiment: Positive
Publish Date: 2024-12-23 16:17:36
Abbott Laboratories said on Monday it and DexCom have reached an agreement to settle all patent disputes between the companies related to continuous glucose monitoring devices.
Sentiment: Positive
Publish Date: 2024-12-23 07:31:07
DexCom (DXCM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Sentiment: Negative
Publish Date: 2024-12-21 06:45:00
Shares of the medical-device maker DexCom (DXCM 5.57%) are down by 37% this year. The diabetes-focused healthcare company disappointed investors with its second-quarter results, leading to a massive drop in its stock price overnight.
Sentiment: Neutral
Publish Date: 2024-12-20 09:01:16
Two S&P 500 stocks--DexCom and Albemarle--are already on sale for investors to buy in 2025.
Sentiment: Positive
Publish Date: 2024-12-19 08:30:00
NEW YORK--(BUSINESS WIRE)--EDO, the TV outcomes company, has released its Q3 2024 Diabetes Convergent TV Outcomes Report, providing critical insights into the diabetes category linear and streaming TV ad performance. The report reveals actionable findings on what drives consumer engagement in this category, with GLP-1 drugs reshaping the landscape of diabetes management and advertisers increasingly investing in convergent TV to target this growing audience. Consumer engagement – measured by act.
Sentiment: Positive
Publish Date: 2024-12-18 11:35:16
Dexcom announces the first Generative AI platform in glucose biosensing.
Sentiment: Neutral
Publish Date: 2024-12-17 09:00:01
Dexcom on Tuesday announced its first generative AI feature for its Stelo biosensor that gives users a personalized weekly report about their glucose. The company has been building a generative AI platform with technology from Google Cloud.
Sentiment: Positive
Publish Date: 2024-12-17 09:00:00
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today it has launched a proprietary Generative AI (GenAI) platform, making Dexcom the first CGM manufacturer to integrate GenAI into glucose biosensing technology.1 The new Dexcom GenAI platform will analyze individual health data patterns to reveal a direct association between lifestyle choices and glucose levels while providing actionable insights to help improve metabolic health. Stelo,.
Sentiment: Positive
Publish Date: 2024-12-17 08:00:00
BURNABY, British Columbia--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ: DXCM), a global leader in glucose biosensing technology, is proud to announce that the Dexcom G7 Continuous Glucose Monitoring (CGM) System has now been added to the Alberta Drug Benefit List. In addition, the Alberta government has expanded the eligibility criteria* to also include adults ages 18 and older. Alberta residents living with type 1 or type 2 diabetes who are enrolled in a government-sponsored health benefit plan† and.
Sentiment: Positive
Publish Date: 2024-12-13 09:01:16
DXCM continues to raise optimism among investors owing to its strong product portfolio.
Sentiment: Positive
Publish Date: 2024-12-10 15:18:54
DexCom faces challenges in 2024 due to competition and missteps, but the long-term outlook for continuous glucose monitors remains strong. Q3 revenue grew only 2% y/y to $994.2 million, with temporary and long-lasting headwinds impacting growth and margins. The new over-the-counter Stelo CGM launched in August, offering a new growth vector and targeting non-insulin users, with significant ramp-up expected in 2025.
Sentiment: Positive
Publish Date: 2024-12-05 07:00:00
The S&P is up 27% in 2024, including a 5.5% rally in November. The Euphoria index is at record highs, indicating investor sentiment is extremely bullish. While 2025 is likely to see much larger volatility, there are still many excellent blue-chip opportunities to buy for a potentially significant 2025. Here are 11 Ultra Sleep Well At Night quality companies that are 45% undervalued, growing at 18%, with an 85% average fundamentally justified return potential in 2025.
* The sentiment analysis presented is generated through an algorithm and may be subject to inaccuracies. Users are advised to corroborate key information and employ further analytical methods prior to making critical decisions.
Get instant AI-powered professional insights:
💡Generate AI Technical Analysis ReportUnderstand the chart below:
Interpret Technical Indicators
| Indicator | Bullish | Bearish |
|---|---|---|
| Price and EMA ⓘ | Price crosses above EMA | Price crosses below EMA |
| Short-Term vs Long-Term EMA ⓘ | Short EMA crosses above Long EMA | Short EMA crosses below Long EMA |
| Volume ⓘ | Increasing volume during price uptrend | Increasing volume during price downtrend |
| MACD ⓘ | MACD crosses above Signal Line | MACD crosses below Signal Line |
| RSI ⓘ | RSI is below 30 (oversold) and starts to rise above 30 | RSI is above 70 (overbought) and starts to decline below 70 |
| Candlestick Patterns ⓘ | Bullish candlestick patterns | Bearish candlestick patterns |
Copyright © 2024 Sirius Investors
All rights reserved
